Dr. Jais Bjelke, PhD

Principal Scientist at Novo Nordisk AS

Speaker

Jais Rose Bjelke, PhD, obtained his doctorate in Haemostasias Biochemistry in 2006, following a Master’s degree in Human Biology and a Bachelor’s degree in Molecular Biology. With a tenure at Novo Nordisk of 22 years, he currently holds the position of Principal Scientist and Technology Project Coordinator in the Global Research Unit. Throughout his career, he has played a pivotal role in numerous haemophilia, inflammation and other biopharmaceutical drug projects. Notably, his contributions were instrumental in the research and development of Rebinyn/Refixia (nonacog beta pegol), a long-acting coagulation factor IX drug approved by both the FDA and EMA, and of the coagulation factor VIII-mimicking bispecific antibody Mim8, which is in phase 3 clinical trial.